Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study
Considering the safety data, exposures and potential MDA operational aspects, 8 mg for children aged between 8 and 11 years and 4 mg for children aged between 4 and 7 years were selected for further single-dose studies.
Authors
- Mariëlle van Zutphen‐van Geffen
- Sally Kinrade (ORCID: https://orcid.org/0000-0001-8510-4455)
- Bismark S. Donkor
- Kashyap Patel (ORCID: https://orcid.org/0000-0002-8790-906X)
- Annette C. Kuesel (ORCID: https://orcid.org/0000-0002-1696-1784)
- Felix Doe
- Nicholas Opoku (ORCID: https://orcid.org/0000-0001-9495-8874)
- Craig R. Rayner (ORCID: https://orcid.org/0000-0001-7755-6419)
- Shelter K. Gordor
- Rukaya Laryea
- Melinda Lowe (ORCID: https://orcid.org/0000-0003-3624-9425)
- D. Navarro
- Mannel E. Agbogah
- Edwin Anyomitse
- Dickson Kugali
Institutions
- Center for Global Development (US)
- University of Health and Allied Sciences (GH)
- Certara (United States) (US)
- Integra LifeSciences (United States) (US)
- Monash University (AU)
Publication Details
- Journal
- Parasites & Vectors
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1186/s13071-025-06891-z
- Primary Topic
- Parasitic Diseases Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- European and Developing Countries Clinical Trials Partnership